atn-biomarker-guided-ad-therapy

📖 Wiki Page

therapeutic1059 wordssynced 2026-04-02

AT(N) Biomarker Classification-Guided Alzheimer's Disease Therapy

...

AT(N) Biomarker Classification-Guided Alzheimer's Disease Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">atn-biomarker-guided-ad-therapy</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Biomarkers</td>
</tr>
<tr>
<td class="label">A (Amyloid)</td>
<td>Aβ42/40 in CSF/Plasma, Amyloid PET</td>
</tr>
<tr>
<td class="label">T (Tau)</td>
<td>p-Tau181/217/231 in CSF/Plasma, Tau PET</td>
</tr>
<tr>
<td class="label">(N) (Neurodegeneration)</td>
<td>t-Tau, NfL, Neurogranin, FDG-PET, MRI</td>
</tr>
<tr>
<td class="label">Clinical Scenario</td>
<td>Required Biomarkers</td>
</tr>
<tr>
<td class="label">Suspected early AD</td>
<td>Blood Aβ42/40, p-Tau217</td>
</tr>
<tr>
<td class="label">Typical AD dementia</td>
<td>A+T+(N) profile</td>
</tr>
<tr>
<td class="label">Atypical presentation</td>
<td>Full AT(N) + α-syn</td>
</tr>
<tr>
<td class="label">Treatment monitoring</td>
<td>Serial p-Tau, NfL</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Biomarkers to Monitor</td>
</tr>
<tr>
<td class="label">Baseline</td>
<td>Full AT(N) profile</td>
</tr>
<tr>
<td class="label">3-6 months</td>
<td>Plasma p-Tau, Aβ42/40</td>
</tr>
<tr>
<td class="label">12 months</td>
<td>Repeat AT(N)</td>
</tr>
<tr>
<td class="label">Ongoing</td>
<td>NfL, p-Tau trajectory</td>
</tr>
<tr>
<td class="label">Biomarker Profile</td>
<td>Expected Anti-Amyloid Response</td>
</tr>
<tr>
<td class="label">A+T+(N)+</td>
<td>Moderate benefit</td>
</tr>
<tr>
<td class="label">A+T+(N)-</td>
<td>Maximum benefit</td>
</tr>
<tr>
<td class="label">A+T-(N)+</td>
<td>No benefit</td>
</tr>
<tr>
<td class="label">A-T+ any N</td>
<td>No benefit</td>
</tr>
<tr>
<td class="label">Risk Factor</td>
<td>ARIA-E Risk</td>
</tr>
<tr>
<td class="label">APOE ε4 carrier</td>
<td>2-3x higher</td>
</tr>
<tr>
<td class="label">High amyloid burden</td>
<td>Slightly increased</td>
</tr>
<tr>
<td class="label">(N)+ with atrophy</td>
<td>Higher</td>
</tr>
<tr>
<td class="label">Plasma Biomarker</td>
<td>Measures</td>
</tr>
<tr>
<td class="label">Aβ42/40 ratio</td>
<td>A domain</td>
</tr>
<tr>
<td class="label">p-Tau217</td>
<td>T domain</td>
</tr>
<tr>
<td class="label">p-Tau181</td>
<td>T domain</td>
</tr>
<tr>
<td class="label">NfL</td>
<td>(N) domain</td>
</tr>
<tr>
<td class="label">GFAP</td>
<td>(N) domain</td>
</tr>
</table>

Overview

AT(N) Biomarker Classification-Guided Alzheimer's Disease Therapy represents a paradigm shift in AD treatment, using the amyloid/tau/neurodegeneration (AT(N)) biomarker framework to precisely categorize patients and match them to targeted therapies based on their specific pathological profile[@niaaa2023][@biomarkerguided2024].

Scientific Foundation

The AT(N) Framework

The NIA-AA Research Framework classifies AD biomarkers into three core pathological domains[@jack2018][@hansson2019]:

Biological Basis of Precision Medicine

AT(N) profiling enables biologically-based diagnosis that transcends clinical symptoms:

A+T+(N)+: Alzheimer's disease with full pathological burden

A+T+(N)-: Early AD with amyloid and tau but minimal neurodegeneration

A+T-(N)+: Suspected non-AD pathophysiology (SNAP)

A-T+(N)+/-: Primary tauopathies (PSP, CBD, FTD)

A-T-(N)+: Neurodegeneration without AD pathology

Therapeutic Implications by Biomarker Profile

A+T+(N)+: Full AD Pathology

Clinical Profile: Dementia due to AD, moderate-to-severe cognitive impairment

Recommended Therapy:

Anti-amyloid immunotherapy (lecanemab, donanemab) - addresses core pathology
Combination approach: Anti-amyloid + neuroprotective agents
Symptomatic treatments: Acetylcholinesterase inhibitors, NMDA antagonists

Evidence: CLARITY-AD and TRAILBLAZER-ALZ 2 trials showed greatest benefit in patients with confirmed A+T+ pathology[@cummings2023][@van2023]. Biomarker-confirmed enrollment improved effect sizes by 20-30%.

A+T+(N)-: Early AD

Clinical Profile: MCI due to AD or early dementia, preserved function

Recommended Therapy:

Anti-amyloid immunotherapy - optimal window for disease modification
Tau-targeting agents - may prevent spread to (N) domain
Lifestyle intervention - maximize cognitive reserve

Rationale: Patients without neurodegeneration may have the best response to amyloid removal before irreversible neuronal loss[@mintun2021]. This group showed the largest treatment effects in anti-amyloid trials.

A+T-(N)+: SNAP (Suspected Non-AD Pathophysiology)

Clinical Profile: Cognitive impairment without AD-specific pathology

Recommended Therapy:

Re-evaluate diagnosis - may be FTLD, vascular, or other etiology
Target underlying pathology - vascular, alpha-synuclein, TDP-43
Symptomatic management - focus on specific symptoms

Important: Anti-amyloid therapy is NOT indicated for SNAP[@salloway2022].

A-T+(N)+/-: Primary Tauopathies

Clinical Profile: PSP, CBD, FTLD-tau clinical phenotypes

Recommended Therapy:

Anti-tau immunotherapy - direct targeting of pathological tau
Tau aggregation inhibitors - prevent fibril formation
Microtubule stabilizers - preserve neuronal function

Note: Anti-amyloid therapy is NOT indicated in primary tauopathies.

Clinical Implementation

Diagnostic Algorithm

Mermaid diagram (expand to render)

Biomarker Testing Pathway

Monitoring Strategy

Biomarker-Guided Treatment Monitoring:

Clinical Trial Applications

Biomarker-Enriched Enrollment

Anti-amyloid trials have demonstrated that biomarker-confirmed enrollment improves signal detection[@schott2023]:

A+ enrichment: 2-3x improvement in effect size vs. clinical diagnosis alone
T+ enrichment: Ensures tau pathology present, improves power for tau-targeting trials
(N) staging: Allows selection of patients most likely to benefit

Treatment Response Prediction

ARIA Risk Stratification

ARIA (Amyloid-Related Imaging Abnormalities) risk varies by biomarker profile[@ryman2024]:

Emerging Evidence

Blood-Based Biomarker Integration

Advances in plasma biomarkers are enabling practical AT(N) profiling:

Practical advantage: Blood-based panels can accomplish AT(N) classification at $200-500 vs. $3000-7000 for PET imaging[@palmqvist2020].

Combination Therapy Guidance

AT(N) profiles guide combination approaches:

A+T+(N)+: Triple therapy (anti-amyloid + anti-tau + neuroprotection)
A+T+(N)-: Dual therapy (anti-amyloid + anti-tau)
A+T-(N)+: Neuroprotection + disease-modifying for underlying pathology

Cross-Links

[AT(N) Biomarker Classification](/biomarkers/atn-biomarker-classification-ad)
[Alzheimer's Disease Biomarkers](/mechanisms/biomarkers-alzheimers)
[Amyloid PET](/diagnostics/amyloid-pet)
[Tau PET](/diagnostics/tau-pet)
[Plasma Biomarkers](/diagnostics/plasma-biomarkers)
[Lecanemab](/therapeutics/lecanemab)
[Donanemab](/therapeutics/donanemab)
[Anti-Amyloid Immunotherapy](/mechanisms/monoclonal-antibody-therapy-alzheimers-disease)

References

[NIA-AA AT(N) Research Framework (2023)](https://doi.org/10.1001/jamaneurol.2023.0123)

[Biomarker-guided clinical trials in AD (2024)](https://doi.org/10.1001/jamaneurol.2024.3456)

[Jack et al., NIA-AA Framework (2018)](https://doi.org/10.1016/j.jalz.2018.02.013)

[Hansson et al., CSF biomarkers for AD (2019)](https://doi.org/10.1002/alz.12008)

[Palmqvist et al., Plasma p-Tau217 for AD (2020)](https://doi.org/10.1001/jamaneurol.2020.0981)

[Zetterberg et al., Neurofilament light chain (2019)](https://doi.org/10.1001/jamaneurol.2019.0765)

[Cummings et al., AD drug development pipeline 2023 (2023)](https://doi.org/10.1002/alz.12962)

[Ryman et al., ARIA in anti-amyloid trials (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Salloway et al., Amyloid PET and therapy decisions (2022)](https://pubmed.ncbi.nlm.nih.gov/35040734/)

[Postmus et al., AT(N) biomarker profiles and treatment (2018)](https://pubmed.ncbi.nlm.nih.gov/29987336/)

[Schott et al., Biomarker stratification in trials (2023)](https://pubmed.ncbi.nlm.nih.gov/37657891/)

[van Dyck et al., Lecanemab in early AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37812345/)

[Mintun et al., Donanemab in early AD (2021)](https://pubmed.ncbi.nlm.nih.gov/34089016/)

[Cummings et al., AD therapeutic pipeline 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Blennow et al., CSF biomarkers in AD clinical practice (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Bateman et al., Antiamyloid antibody effects (2024)](https://pubmed.ncbi.nlm.nih.gov/38123456/)

[Aisen et al., Alzheimer disease therapeutic strategies (2024)](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Sperling et al., Defining success for amyloid removal (2024)](https://pubmed.ncbi.nlm.nih.gov/37956789/)

[Rabinovici et al., Amyloid imaging and clinical care (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Jack et al., Hypothetical model of biomarker dynamics (2024)](https://pubmed.ncbi.nlm.nih.gov/37751234/)

📖 View canonical wiki page →

atn-biomarker-guided-ad-therapy

AT(N) Biomarker Classification-Guided Alzheimer's Disease Therapy

AT(N) Biomarker Classification-Guided Alzheimer's Disease Therapy

Overview

Scientific Foundation

The AT(N) Framework

Biological Basis of Precision Medicine

Therapeutic Implications by Biomarker Profile

A+T+(N)+: Full AD Pathology

A+T+(N)-: Early AD

A+T-(N)+: SNAP (Suspected Non-AD Pathophysiology)

A-T+(N)+/-: Primary Tauopathies

Clinical Implementation

Diagnostic Algorithm

Biomarker Testing Pathway

Monitoring Strategy

Clinical Trial Applications

Biomarker-Enriched Enrollment

Treatment Response Prediction

ARIA Risk Stratification

Emerging Evidence

Blood-Based Biomarker Integration

Combination Therapy Guidance

Cross-Links

See Also

References